Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL J GOLDSTEIN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1063410645
CMS profile
2193
Location
GREAT NECK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$267.73

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $267.73 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
INTUITIVE SURGICAL, INC. $267.73 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL J GOLDSTEIN

NPI 1063410645 · CMS profile ID 2193

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

GREAT NECK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063410645?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL J GOLDSTEIN, NPI 1063410645, CMS profile ID 2193. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063410645?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MICHAEL J GOLDSTEIN, NPI 1063410645, CMS profile ID 2193. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063410645?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MICHAEL J GOLDSTEIN, NPI 1063410645, CMS profile ID 2193, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1063410645?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $267.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
INTUITIVE SURGICAL, INC. $248.7310/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236646290 CMS
INTUITIVE SURGICAL, INC. $19.0010/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236646292 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $622.74 34
PY2020 $554.05 32
PY2021 $303.05 16
PY2022 $155.50 9
PY2023 $187.37 4
PY2025 $267.73 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $88,071.47 22
PY2023 Principal investigator $169,779.57 14
PY2022 Principal investigator $32,010.78 12
PY2021 Recipient $3,971.40 2
PY2021 Principal investigator $162,998.92 79
PY2020 Principal investigator $489,931.11 140
PY2019 Recipient $883.66 5
PY2019 Principal investigator $583,175.74 159

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $175.00 12/22/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793116347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $471.63 12/22/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793116349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $735.25 12/16/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793115693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,228.32 11/18/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793114249
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 11/02/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816773117
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $196.65 10/19/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816768193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,778.50 10/07/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793111419
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,018.80 09/29/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816762087
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $3,252.75 09/10/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 831594653
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $5,608.63 09/10/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 831596931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,775.38 09/09/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793109657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $471.63 09/09/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793109659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.38 09/09/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793109661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 09/09/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793109663
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $525.00 08/31/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816756343
Recipient Braintree Laboratories, Inc. $1,500.00 08/19/2021 Covered Recipient Physician BLI4900-302 No dispute reported 06/30/2026 805278773
Recipient Braintree Laboratories, Inc. $2,471.40 08/19/2021 Covered Recipient Physician BLI4900-302 No dispute reported 06/30/2026 805278779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,741.15 08/19/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793108399
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $500.00 08/06/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 831598295
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,844.00 07/27/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816746759
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 07/20/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816742391
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $460.00 07/02/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 831595693
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $205.00 07/02/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 831596921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $314.42 06/30/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793105157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $175.00 06/30/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793105159
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $441.75 06/09/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-301 No dispute reported 06/30/2026 831592277
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $500.00 06/09/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-301 No dispute reported 06/30/2026 831598287
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $250.00 06/08/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816730451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,538.24 06/03/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793103569
Principal investigator 1 Braintree Laboratories, Inc. $1,500.00 05/27/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 805280795
Principal investigator 1 Braintree Laboratories, Inc. $5,824.90 05/27/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 805280801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $590.80 05/13/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793102255
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,655.60 05/13/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION (BOS) FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 816723371
Principal investigator 1 Celgene Corporation $7,667.50 05/06/2021 Non-covered Recipient Entity
Long Island Gastrointestinal Research Group
A Multi-Center, Multi-National, Randomized, Double No dispute reported 06/30/2026 807113995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,507.60 05/04/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816719365
Principal investigator 1 Braintree Laboratories, Inc. $200.00 04/26/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 805280255
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,073.20 04/22/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION (BOS) FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 816714927
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 04/22/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION (BOS) FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 816714935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25.00 04/22/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION (BOS) FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 816714945
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,103.20 04/22/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION (BOS) FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 816714954
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $30.00 04/22/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION (BOS) FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 816714959
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,000.00 04/21/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 831598277
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 04/20/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816714539
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $842.20 04/20/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816714549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,470.03 04/15/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793100475
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 04/13/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION (BOS) FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 816708151
Principal investigator 1 Braintree Laboratories, Inc. $5,862.76 03/29/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-302 No dispute reported 06/30/2026 805280101
Principal investigator 1 Braintree Laboratories, Inc. $1,254.01 03/29/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-302 No dispute reported 06/30/2026 805280107
Principal investigator 1 Braintree Laboratories, Inc. $90.00 03/29/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-302 No dispute reported 06/30/2026 805280113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $590.80 03/25/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793099365
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $150.00 03/18/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 831593401
Principal investigator 1 Allergan, Inc. $5,356.50 03/17/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 789004949
Principal investigator 1 Braintree Laboratories, Inc. $990.00 03/16/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 805279989
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,466.80 03/16/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816698241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $735.25 03/04/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793097675
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 03/02/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816694595
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 03/02/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816694605
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,933.60 03/02/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816694615
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,005.30 02/23/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816692085
Principal investigator 1 Allergan, Inc. $487.25 02/18/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 789004947
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,155.60 02/17/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816690645
Principal investigator 1 Braintree Laboratories, Inc. $512.10 02/15/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 805279653
Principal investigator 1 Allergan, Inc. $1,969.00 02/05/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 789004945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,827.32 02/04/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 793094025
Principal investigator 1 Allergan, Inc. $586.80 02/02/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 789004943
Principal investigator 1 Allergan, Inc. $760.75 02/01/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 789004941
Principal investigator 1 Braintree Laboratories, Inc. $4,652.55 02/01/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 805279541
Principal investigator 1 Braintree Laboratories, Inc. $100.00 02/01/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 805279547
Principal investigator 1 Braintree Laboratories, Inc. $100.00 02/01/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 805279553
Principal investigator 1 Braintree Laboratories, Inc. $15,036.12 01/29/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-302 No dispute reported 06/30/2026 805279351
Principal investigator 1 Braintree Laboratories, Inc. $100.00 01/29/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-302 No dispute reported 06/30/2026 805279357
Principal investigator 1 Allergan, Inc. $1,513.25 01/26/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 789004939
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,068.90 01/26/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816685353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 01/20/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816682473
Principal investigator 1 Allergan, Inc. $1,500.00 01/12/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 789004935
Principal investigator 1 Allergan, Inc. $1,500.00 01/12/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 789004937
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $20.00 01/06/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-301 No dispute reported 06/30/2026 831592267
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $4,125.75 01/06/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-301 No dispute reported 06/30/2026 831593391
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $760.00 01/06/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-301 No dispute reported 06/30/2026 831595683
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $65.00 01/06/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-301 No dispute reported 06/30/2026 831596911
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $4,000.00 01/06/2021 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-301 No dispute reported 06/30/2026 831599587